“In future, PBB supported by Rusnano plan to build a new pharmaceutical production facility in Russia that will incorporate the latest production technology and that will meet Russian and international GMP standards. In Great Britain, the partners will create a European marketing and distribution center that will also have additional production capacity,” the statement said.
John Mayo, CEO at Pro Bono, sounded very optimistic commenting on the move and said he expected it to change the global outlook for pharmaceutical industry.
“PBB is an ambitious international pharmaceutical business that will have considerable impact on the world’s healthcare. Thanks to its impressive product line up and innovative business model, PBB will be able to produce excellent financial returns and deliver its humanitarian objectives,” Mayo said.
Rusnano CEO Anatoly Chubais in turn expected Russian healthcare to largely benefit from foreign technology.
“Rusnano Capital executes certain activities for Rusnano. It is co-investor in international nanotechnology projects with significant economic or social potential. This project combines both elements. Pro Bono Bio’s Sequessome technology is an example of nanotech that can considerably improve the treatment of range of important diseases which have a considerable impact on the Russian healthcare system,” Chubais said.